FAB.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold FAB.L in your mock portfolio yet.
Fusion Antibodies is currently loss-making, as indicated by its negative EPS and negative PE ratio. The lack of profitability suggests ongoing operational or scale challenges, and without evidence of strong revenue growth or a clear path to break-even, the financial profile remains weak from a public-equity perspective.
The stock has fallen 24.7% over the last month, signaling strong recent selling pressure. While the current price is above the 200-day moving average, the RSI near 40 suggests momentum is weak and not yet in oversold territory, leaving room for further downside if negative sentiment persists.
Alternative data show limited growth or even mild deterioration in external engagement. Web traffic is very low, hiring activity is flat at zero openings, and social media followership on key platforms is stagnating or slightly declining, all of which suggest muted commercial traction and brand momentum.
Overall, Fusion Antibodies’ profile appears bearish: the company is loss-making, the share price has sold off sharply in the past month, and alternative data show weak or stagnant engagement and growth signals. While trading above its 200-day moving average offers some technical support, the combination of negative earnings, recent price pressure, and subdued external traction tilts the risk-reward toward the downside in the near term.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: